News | September 17, 2009

iCAD Announces Educational Initiatives on New Prostate Imaging Technologies

iCAD's VividLook


September 16, 2009 - iCAD Inc. will host a series of educational events designed for radiologists, urologists, oncologists, radiation oncologists, surgeons, technologists and other referring physicians who diagnose and treat patients with prostate cancer.

Two webinars, entitled “Prostate MRI – A Paradigm Shift in Prostate Cancer Diagnosis and Management” will focus on how MRI combined with an advanced quantitative image analysis software solution, (iCAD’s VividLook), supports improved prostate cancer management. The course will include clinical case reviews that will demonstrate prostate cancer detection in patients with previously negative prostate biopsy and rising PSA, as well as the use of dynamic contrast enhanced (DCE) MRI and Computer-Aided Detection (CAD) to monitor prostate cancer response to radiation therapy.

They will be held on:
· October 15, 2009, at noon ET, with Dr. François Cornud, diagnostic and interventional radiologist at the Centre d’Imagerie Tourville
· November 10, 2009, at 3 pm ET, with Dr. Russell Low, medical director at Sharp and Children’s MRI Center and Assistant Clinical Professor at the University of California San Diego School of Medicine.

In addition, a non-RSNA satellite symposium will be held on Tuesday, December 1, 2009 at 7am CT at the Hyatt Regency in Chicago, room CC24BC. The session, “How quantitative image analysis CAD and MRI play an integral role in prostate cancer programs including pre-biopsy guidance, treatment planning, active surveillance and therapy response monitoring,” will include presentations by clinical experts, Dr. Cornud and Dr. Low. Specific focus areas include how DCE MRI in conjunction with other MRI imaging techniques can improve the sensitivity and specificity of prostate cancer localization and detection as compared to current imaging practices. Specific case examples will be shared, including how DCE MRI and CAD support improved treatment planning for patients undergoing Cyberknife therapy.

For more information: www.icadmed.com

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
3D Systems Announces On Demand Anatomical Modeling Service
Technology | Medical 3-D Printing | June 18, 2018
3D Systems announced availability of its new On Demand Anatomical Modeling Service. This new service provides a wide...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
Technology | Orthopedic Imaging | June 13, 2018
EOS imaging announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its hipEOS...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
Overlay Init